Form 8-K - Current report:
SEC Accession No. 0001213900-25-053576
Filing Date
2025-06-12
Accepted
2025-06-11 21:38:23
Documents
14
Period of Report
2025-06-11
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0245317-8k_denali.htm   iXBRL 8-K 30216
2 PRESS RELEASE, DATED JUNE 11, 2025 ea024531701ex99-1_denali.htm EX-99.1 3969
  Complete submission text file 0001213900-25-053576.txt   252898

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE dnqwf-20250611.xsd EX-101.SCH 4179
4 XBRL DEFINITION FILE dnqwf-20250611_def.xml EX-101.DEF 27310
5 XBRL LABEL FILE dnqwf-20250611_lab.xml EX-101.LAB 37896
6 XBRL PRESENTATION FILE dnqwf-20250611_pre.xml EX-101.PRE 25930
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0245317-8k_denali_htm.xml XML 6847
Mailing Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022
Business Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022 6469785180
Denali Capital Acquisition Corp. (Filer) CIK: 0001913577 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41351 | Film No.: 251041545
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)